Recruiting
PHASE4
INTERVENTIONAL
NCT06843044
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
Interventions
Name:
Ranquilon
Type:
DRUG
Description:
1 mg tablets
Name:
Afobazole
Type:
DRUG
Description:
10 mg tablets
Primary Outcomes
Measure:
The proportion of patients with a significant reduction in anxiety levels (by 50% or more) on Hamilton Anxiety Rating Scale (HARS) compared to baseline on Day 29 ± 1 (Visit 3)
TimeFrame:
Day 29 ± 1 (Visit 3)
Description:
HARS scale includes 14 items, each of which is rated on the Likken scale (from 0 points as absence of the symptom to 4 points as the worst possible symptom). Of these, 13 items relate to the manifestation of anxiety in daily life, 14th item relate to the manifestation of anxiety during examinations.
Trial Information
NCT ID
NCT06843044
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Valenta Pharm JSC
Last Updated
December 15, 2025